

Jared Baeten MD, PhD
Thesla Palanee-Phillips, PhD

ASPIRE Protocol Team Meeting October 2015



Meeting overview

- Welcome back!
- □ Today, we'll cover:
 - Updates on ASPIRE & The Ring Study
 - Looking forward to results and to HOPE (hopefully!)
 - Inspection readiness
- But, first, where we've been and where we are going in ASPIRE

Outline



Where we have been and where we are going – mostly in pictures


We planned a study



A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase III Safety and Effectiveness Trial of a Vaginal Matrix Ring Containing Dapivirine for the Prevention of HIV-1 Infection in Women

with a Ring for Extended Use

We learned the meaning of ASPIRE



aspire(as·pire)

Pronunciation: /əˈspī(ə)r/

verb:

direct one's hopes or ambitions toward achieving something:

we never thought that we might aspire to those heights



noun:

- 1. A Phase III study that seeks to determine whether a woman's use of a vaginal ring containing dapivirine is a safe and effective method for protecting against HIV infection.
- 2. A Study to Prevent Infection with a Ring for Extended Use



dream:

Quote from the qualitative component of ASPIRE:

If we find something that helps us it will not just help me alone but it will also help future generations. This is something which is good.

We started!

Phase III Trial of Dapivirine Ring Begins in Africa: ASPIRE testing new HIV prevention approach for women


WASHINGTON, D.C., July 24, 2012 – A large clinical trial testing the long-term safety and effectiveness of a new approach for preventing HIV in women – a vaginal ring used once a month – is now underway in Africa, researchers announced today at the XIX International AIDS Conference (AIDS 2012).







We worked in 15 Sites across 4 countries



Blantyre Lilongwe **Malawi**


Cape Town
Durban (7 sites)
Johannesburg
South Africa

Kampala **Uganda**

Harare/Chitungwiza (3 sites) **Zimbabwe**



We learned how to explain the ring






We went to the community





We provided exceptional prevention services





We worked together



The Ring Study (IPM 027)



ASPIRE (MTN-020)

Objectives

Study design

Endpoints

Enrollment

Regulatory requirement

Participant follow-up

Research sites

Long-term safety and efficacy

Double-blind, randomized (2:1), placebo-controlled

Expected ~96 endpoints, 2 year on investigational product

Total: 1959 women, ages 18-45 Active arm: ~1300 Safety and effectiveness

Double-blind, randomized (1:1), placebo-controlled

Endpoint driven: ~120 endpoints

Total: 2629 women, ages 18-45
Active arm: ~1315

3000 women on dapivirine ring for at least 1-year follow-up 1500 women on dapivirine ring for 2-year follow-up

2 years + 6 weeks following ring discontinuation

7 IPM research center partners in South Africa and Uganda

Minimum 1 year + 4 weeks following ring discontinuation

15 MTN research centers in Malawi, South Africa, Uganda, Zimbabwe

We defined our Big Five

Accrual

Data Quality and Timeliness


Retention






Adherence


We thought about adherence



No adherence = no HIV protection

And then we thought a lot about adherence





Adherence is Everything


Jared Baeten MD PhD
Thesla Palanee PhD

ASPIRE Adherence Meeting Durban, South Africa 14 March 2013



We did amazing participant engagement









We did amazing participant engagement





We did amazing participant engagement





We looked at returned rings





We made our Big Five a reality





We became a team





We continuously worked in communities





We completed accrual June 2014

Site	First enr	# enr
MA – Blantyre	13 JUN 13	130
MA – Lilongwe	17 JUN 13	142
SA – Cape Town	19 SEP 2012	166
SA – CAPRISA eThekwini	10 OCT2012	244
SA – MRC/Botha's Hill	10 SEP 2012	180
SA – MRC/Chatsworth	11 SEP 2012	150
SA – MRC/Isipingo	19 SEP 2012	117
SA – MRC/Tongaat	17 SEP 2012	103
SA – MRC/Verulam	13 SEP 2012	150
SA – MRC/Umkomaas	14 SEP 2012	103
SA – WRHI	30 OCT 2012	213
UG – Kampala	21 AUG 2012	253
ZI – Seke South	01 NOV 12	224
ZI – Spilhaus	30 OCT 12	230
ZI- Zengeza	13 NOV 12	224
TOTAL		2629



We had amazing retention

OVERALL >91% of all expected visits

>97% of visits excluding early terminations



We reminded the world that PrEP is not one size fits all











Pill

Gel

Vaginal film


Vaginal ring

Injectable

- ✓ Tenofovir-based PrEP is a first proof-of-concept.
- ✓ Ultimate goals: multiple options, long acting, safe, effective, low cost and user-friendly
 - Maximize choice & optimize effectiveness



We diversified contraception





We shipped a lot of samples







We did a lot of phone calls





We learned

- Women are interested in a ring for prevention.
- Real-time adherence monitoring can be done in a trial, and women are adherent to a ring.
- Women want prevention options.
- Contraceptive options matter.
- Male involvement, in many different ways, is part of prevention in women.



We have amazing data

- >600,000 CRF pages.
- >150,000 samples, including >20,000 plasma samples tested.
- >40,000 rings dispensed, returned, and tested.
- 248 IDIs, 12 FGDs.



We planned

2012 2013 2015 2016 2014

IPM 027 (The Ring Study)



Results?

MTN-020 (ASPIRE) ASPIRE



Results

Supporting Safety and PK Studies

Dapivirine Ring Regulatory Consultations



We planned for results

EFFICACY IS CLEAR EFFICACY WITH QUESTIONS RESULTS UNCLEAR INSUFFICIENT EFFICACY

Great news!

Results clearly show dapivirine ring is safe and effective

Move to implement HOPE



Good news (?)

Results show dapivirine ring is safe and effective

Decision about HOPE not straightforward

HOPE
Out of ASPIRE, there is HOPE

Results don't provide clear answers - additional analysis needed?

Results answer the questions - dapivirine ring is safe but not effective



We planned for success





opens

Participants informed

Former Participants contacted

enrollment

Approximately 1-year open- label use of dapivirine ring

IRB/EC informed

HOPE approval



National and community **Stakeholders** informed



We are a team

























School of Medicine









Acknowledgements

MTN is funded by NIAID (UM1AI068633, UM1AI068615, UM1AI06707), NICHD and NIMH, all of the U.S. National Institutes of Health



